Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | Characteristics of patients with B-cell malignancies treated with tisa-cel in the outpatient setting

Nausheen Ahmed, MD, University of Kansas Medical Center, Westwood, KS, outlines the main differences between patients with B-cell malignancies treated with tisagenlecleucel (tisa-cel) in the outpatient versus inpatient settings. Dr Ahmed explains that patients treated in the outpatient setting had more normal lactate dehydrogenase (LDH) levels and had a lower Charlson Comorbidity Index (CCI) score. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

BMS: Advisory Board; KUMC – Kite Pharma: Research Funding